▲ +1,416.60% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is $26.39, with a high forecast of $112.00 and a low forecast of $2.50. The average price target represents a 1,416.60% upside from the last price of $1.74.
The current consensus among 9 polled investment analysts is to hold stock in Corbus Pharmaceuticals. This rating has held steady since August 2020, when it changed from a Buy consensus rating.
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.